Metabolomic Profiles on Antiblastic Cardiotoxicity: New Perspectives for Early Diagnosis and Cardioprotection
Luca Fazzini1, Ludovica Caggiari1, Martino Deidda1
1Department of Medical Sciences and Public Health, University Hospital of Cagliari, Strada Statale 554, Km 4.500, 09042 Monserrato, Italy.
Abstract:
Antiblastic drugs-induced cardiomyopathy remains a relevant cause of morbidity and mortality, during and after chemotherapy, despite the progression in protective therapy against cardiovascular diseases and myocardial function. In the last few decades, many groups of researchers have focused their attention on studying the metabolic profile, first in animals, and, subsequently, in humans, looking for profiles which could be able to predict drug-induced cardiotoxicity and cardiovascular damage. In clinical practice, patients identified as being at risk of developing cardiotoxicity undergo a close follow-up and more tailored therapies. Injury to the heart can be a consequence of both new targeted therapies, such as tyrosine kinase inhibitors, and conventional chemotherapeutic agents, such as anthracyclines. This review aims to describe all of the studies carried on this topic of growing interest.
Insights
Chemotherapy can cause heart damage (cardiotoxicity), leading to serious health issues. Researchers are studying metabolic profiles to predict and prevent this drug-induced cardiomyopathy in at-risk patients.
Area of Science:
- Cardiology
- Oncology
- Pharmacology
Background:
- Antiblastic drugs-induced cardiomyopathy is a significant cause of morbidity and mortality during and after chemotherapy.
- Despite advances in protective therapies, myocardial damage remains a concern.
- Both conventional agents (e.g., anthracyclines) and targeted therapies (e.g., tyrosine kinase inhibitors) can cause cardiotoxicity.
Purpose of the Study:
- To review studies investigating metabolic profiles for predicting drug-induced cardiotoxicity.
- To summarize current knowledge on identifying and managing patients at risk of chemotherapy-related heart damage.
Main Methods:
- Literature review of studies on metabolic profiling in animal models and humans.
- Analysis of research focusing on predictive markers for cardiotoxicity.
- Examination of clinical practices for monitoring and treating at-risk patients.
Main Results:
- Metabolic profiling shows promise in predicting drug-induced cardiotoxicity.
- Early identification of at-risk patients allows for tailored therapies and close follow-up.
- Understanding metabolic signatures can aid in developing preventative strategies.
Conclusions:
- Metabolic profiling is a valuable tool for predicting and potentially preventing antiblastic drug-induced cardiomyopathy.
- Continued research is crucial for refining predictive models and therapeutic interventions.
- Personalized medicine approaches are essential for managing cardiovascular risks in cancer patients.
